1. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Issue 10323 (29th January 2022) Authors: Bravo, Lulu; Smolenov, Igor; Han, Htay Htay; Li, Ping; Hosain, Romana; Rockhold, Frank; Clemens, Sue Ann Costa; Roa, Camilo; Borja-Tabora, Charissa; Quinsaat, Antoinette; Lopez, Pio; López-Medina, Eduardo; Brochado, Leonardo; Hernández, Eder A; Reynales, Humberto; Medina, Tatiana; Velasquez, Hect... Journal: Lancet Issue: Volume 399:Issue 10323(2022) Page Start: 461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study. Issue 11 (10th March 2023) Authors: Buntinx, Erik; Brochado, Leonardo; Borja-Tabora, Charissa; Yu, Charles Y.; Alberto, Edison R; Montellano, May Emmeline B.; Carlos, Josefina C.; Toloza, Leonardo Bautista; Hites, Maya; Siber, George; Clemens, Ralf; Ambrosino, Donna; Qin, Haijing; Chen, Hui Ling; Han, Htay Htay; Hu, Branda; Li, Pin... Journal: Vaccine Issue: Volume 41:Issue 11(2023) Page Start: 1875 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. (19th November 2021) Authors: Ambrosino, Donna; Han, Htay Htay; Hu, Branda; Liang, Joshua; Clemens, Ralf; Johnson, Marina; Siber, George; Goldblatt, David Journal: Journal of infectious diseases Issue: Volume 225:Number 2(2022) Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. Issue 7 (July 2022) Authors: Smolenov, Igor; Han, Htay Htay; Li, Ping; Baccarini, Carmen; Verhoeven, Carole; Rockhold, Frank; Clemens, Sue Ann Costa; Ambrosino, Donna; Richmond, Peter; Siber, George; Liang, Joshua; Clemens, Ralf Journal: Lancet infectious diseases Issue: Volume 22:Issue 7(2022) Page Start: 990 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021. Issue 32 (30th July 2022) Authors: Gilbert, Peter B.; Isbrucker, Richard; Andrews, Nick; Goldblatt, David; Heath, Paul T.; Izu, Alane; Madhi, Shabir A.; Moulton, Lawrence; Schrag, Stephanie J.; Shang, Nong; Siber, George; Sobanjo-ter Meulen, Ajoke Journal: Vaccine Issue: Volume 40:Issue 32(2022) Page Start: 4283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Issue 31 (29th July 2022) Authors: Chichili, Gurunadh R.; Smulders, Ronald; Santos, Vicki; Cywin, Beth; Kovanda, Laura; Van Sant, Charles; Malinoski, Frank; Sebastian, Shite; Siber, George; Malley, Richard Journal: Vaccine Issue: Volume 40:Issue 31(2022) Page Start: 4190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Towards a population-based threshold of protection for COVID-19 vaccines. Issue 2 (21st January 2022) Authors: Goldblatt, David; Fiore-Gartland, Andrew; Johnson, Marina; Hunt, Adam; Bengt, Christopher; Zavadska, Dace; Snipe, Hilda Darta; Brown, Jeremy S.; Workman, Lesley; Zar, Heather J.; Montefiori, David; Shen, Xiaoying; Dull, Peter; Plotkin, Stanley; Siber, George; Ambrosino, Donna Journal: Vaccine Issue: Volume 40:Issue 2(2022) Page Start: 306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗